Finding accredited CPD
This is a study review on FLOW, a trial assessing the impact of once-weekly semaglutide on kidney outcomes in patients with both chronic kidney disease and type 2 diabetes.
Independent commentary for the review has been provided by Dr Richard Phoon, a senior medical advisor, nephrologist, an experienced non executive director and principal investigator on several international clinical trials.
This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.
Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.
*Medical Board of Australia’s (MBA)’s Registration Standard: Continuing professional development (the Standard)
